title: Propinox in intestinal colic: multicenter randomized prospective double-blind study of three doses of propinox vs. placebo in acute intestinal colic pain.
abstract: The aim of this double-blind study was to assess the efficacy and tolerability of propinox administered i.v. and to establish a dose-response relationship according to three dose levels (10 mg, 20 mg and 30 mg), vs. placebo in patients with moderate-to-severe acute intestinal colic pain. Four hundred patients (100 per treatment group) were included and allocated to the following treatment groups: propinox 10 mg, 20 mg, 30 mg and placebo. All treatments induced significant and progressive pain reduction as from the 20 min evaluation of 20.3% in the placebo group, 45% in the group treated with propinox 10 mg; 52% in the group receiving propinox 20 mg and 56% in the propinox 30 mg group. Statistical comparison showed differences between placebo and the three active doses as well as between propinox 10 mg and the 20 mg and 30 mg doses. The 20 min evaluation revealed that 40% of patients receiving placebo had to be excluded from the study due to lack of efficacy; the percentage of which was significantly higher compared with those observed with the three doses of propinox ranging between 10% and 13%. The 120 min evaluation revealed that 47.7% of patients treated with propinox 10 mg were free from pain vs. 68.8% and 73.5% of those receiving 20 mg and 30 mg, respectively. These percentages were considerably higher than the 15% found with placebo. Statistical analysis revealed significant differences between the 10 mg vs. the 20 mg and 30 mg groups with not differences between the latter doses. No differences in blood pressure or heart rate were found among treatments. The incidence of mouth dryness was significantly more frequent with the 20 mg and 30 mg doses of propinox than with the placebo or the 10 mg dose.
authors.affiliation: School of Medicine, Department of Pharmacology, Universidad de Buenos Aires, Argentina.
authors.forename: G
authors.initials: G
authors.lastname: Di Girolamo
authors.forename: A R
authors.initials: AR
authors.lastname: de los Santos
authors.forename: M L
authors.initials: ML
authors.lastname: Martí
authors.forename: E
authors.initials: E
authors.lastname: Valdés Quintana
authors.forename: M I
authors.initials: MI
authors.lastname: Godoy
authors.forename: M A
authors.initials: MA
authors.lastname: Morano
authors.forename: G
authors.initials: G
authors.lastname: Palomino
authors.forename: D
authors.initials: D
authors.lastname: Fandiño
authors.forename: A
authors.initials: A
authors.lastname: Greggio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D016009:Chi-Square Distribution; D003085:Colic / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D008875:Middle Aged; D010147:Pain Measurement / Q000187:drug effects*
chemical_list: D008333:Mandelic Acids; C087283:propinox